NCT07140744

A Study Evaluating the Impact of P-tau217 Blood Biomarker Testing on Early Evaluation and Management of Patients Presenting With Cognitive Complaint

A Prospective Diagnostic Study Evaluating the Impact of P-tau217 Blood Biomarker Testing on Early Evaluation and Management of Patients Presenting With Cognitive Complaint in Primary and Secondary/Tertiary Care

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 7,000 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to measure the difference in the proportion of participants with prespecified patient management actions between a tested interventional group and a control group.

Detailed description

There are two types of participants in this study, HCP participants and patient participants. Outcome measures relate to the HCP management of patient participants.

Conditions

• Subjective Cognitive Impairment

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	P-tau217	Blood biomarker testing
OTHER	Standard of Care	Standard of care

Timeline

• Start date: 2025-08-22
• Primary completion: 2027-10-01
• Completion: 2027-10-01
• First posted: 2025-08-26
• Last updated: 2025-11-03

Locations

1 site across 1 country: United States